- Home
- EBC vs ELVN Comparison
EBC vs ELVN Comparison
Compare EBC & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EBC | ELVN |
|---|---|---|
| Founded | 1818 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Accident &Health Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.2B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | EBC | ELVN |
|---|---|---|
| Price | $21.04 | $46.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | $25.13 | ★ $73.90 |
| AVG Volume (30 Days) | ★ 1.9M | 1.1M |
| Earning Date | 10-22-2026 | 11-11-2026 |
| Dividend Yield | ★ 2.87% | N/A |
| EPS Growth | N/A | ★ 3.17 |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $134,091,000.00 | N/A |
| Revenue This Year | $21.18 | N/A |
| Revenue Next Year | $4.62 | N/A |
| P/E Ratio | $27.25 | ★ N/A |
| Revenue Growth | ★ 19.07 | N/A |
| 52 Week Low | $16.62 | $14.79 |
| 52 Week High | $23.78 | $62.32 |
Technical Indicators
Market Signals| Indicator | EBC | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 27.94 | 28.85 |
| Support Level | $19.12 | $25.63 |
| Resistance Level | $20.89 | $48.53 |
| Average True Range (ATR) | 0.37 | 2.06 |
| MACD | -0.05 | -0.42 |
| Stochastic Oscillator | 0.66 | 16.09 |
Price Performance
Historical ComparisonAbout EBC Eastern Bankshares Inc.
Eastern Bankshares Inc is a commercial bank that caters its products and services to retail, commercial, and small business customers. Its diversified products and services include lending, deposit, wealth management, and insurance products. The company has one operating segment: Banking business, which offers a range of banking, lending, savings, and small business offerings, and its wealth management and trust operations.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.